David M Vollmer

US Patent:

20060004076, Jan 5, 2006

Filed:

Jun 3, 2005

Appl. No.:

11/145024

Inventors:

Dinesh Patel - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
John Gebhard - Salt Lake City UT, US

International Classification:

A61K 31/415
A61K 31/202

US Classification:

514406000, 514560000, 514547000

Abstract:

The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with at least one other pharmaceutically active agent to reduce inflammation.

US Patent:

20060122160, Jun 8, 2006

Filed:

Nov 8, 2005

Appl. No.:

11/270326

Inventors:

Dinesh Patel - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
John Gebhard - Salt Lake City UT, US

International Classification:

A61K 31/57
A61K 31/365

US Classification:

514171000, 514468000

Abstract:

The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with a parthenolide to reduce inflammation.

US Patent:

20060154908, Jul 13, 2006

Filed:

Jan 26, 2006

Appl. No.:

11/342276

Inventors:

Dinesh Patel - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
John Gebhard - Salt Lake City UT, US

International Classification:

A61K 31/57

US Classification:

514171000

Abstract:

The present invention is drawn to compositions and methods for treating depression in a subject comprising co-administering therapeutically effective amounts of a DHEA congener and a second antidepressant agent to the subject, wherein the step of co-administrating is more effective in producing an anti-depressive effect compared to the administration of either the DHEA congener or the second antidepressant agent alone at their respective dosages.

US Patent:

20060217355, Sep 28, 2006

Filed:

Mar 6, 2006

Appl. No.:

11/370218

Inventors:

Dinesh Patel - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
John Gebhard - Salt Lake City UT, US

International Classification:

A61K 31/53
A61K 31/365
A61K 31/415

US Classification:

514171000, 514406000, 514471000

Abstract:

The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with at least one other pharmaceutically active agent to treat or prevent cancer.

US Patent:

20080233135, Sep 25, 2008

Filed:

Mar 14, 2008

Appl. No.:

12/077060

Inventors:

John R. Gebhard - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
Dinesh Patel - Salt Lake City UT, US

International Classification:

A61K 47/48
A61K 31/714
C07H 23/00
A61P 35/00

US Classification:

4241781, 514 52, 536 264, 5303871

Abstract:

The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.

US Patent:

20120015900, Jan 19, 2012

Filed:

Jul 22, 2011

Appl. No.:

13/188903

Inventors:

John R. Gebhard - Cottonwood Heights UT, US
David Vollmer - West Jordan UT, US
Claire Daugherty - Salt Lake City UT, US
Dinesh Patel - Salt Lake City UT, US

Assignee:

Osiris Therapeutics, Inc. - Columbia MD

International Classification:

A61K 31/714
A61P 35/00
A61P 35/02
C07H 23/00

US Classification:

514 52, 536 264

Abstract:

The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.

US Patent:

20210002233, Jan 7, 2021

Filed:

Jul 15, 2020

Appl. No.:

16/930254

Inventors:

- Cambridge MA, US
Yong XU - Midvale UT, US
Michael David SAUNDERS - Sandy UT, US
Xiaohui LIU - Holladay UT, US
Scott Albert PEARCE - Clearfield UT, US
Kevin Bret WRIGHT - Cottonwood Heights UT, US
Jason Marc FOULKS - Sandy UT, US
Kenneth Mark PARNELL - Kaysville UT, US
Steven Brian KANNER - Salt Lake City UT, US
David Lee VOLLMER - South Jordan UT, US
Jihua LIU - San Marcos CA, US

International Classification:

C07D 231/14
C07D 231/38
C07F 9/6503
C07D 403/12
C07D 401/14
C07D 405/14
C07D 231/16
C07D 401/12
C07D 403/14
C07D 405/12
C07D 409/12
C07D 409/14
C07D 413/12
C07D 417/12
C07D 417/14
A61P 11/00
A61P 43/00
A61P 35/00
A61K 31/4155

Abstract:

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I):including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

US Patent:

20200109120, Apr 9, 2020

Filed:

Sep 26, 2019

Appl. No.:

16/584912

Inventors:

- Lehi UT, US
Yong XU - Midvale UT, US
Michael David SAUNDERS - Sandy UT, US
Xiaohui LIU - Holladay UT, US
Scott Albert PEARCE - Clearfield UT, US
Kevin Bret WRIGHT - Cottonwood Heights UT, US
Jason Marc FOULKS - Sandy UT, US
Kenneth Mark PARNELL - Kaysville UT, US
Steven Brian KANNER - Salt Lake City UT, US
David Lee VOLLMER - South Jordan UT, US
Jihua LIU - San Marcos CA, US

International Classification:

C07D 231/14
C07D 231/38
C07F 9/6503
C07D 403/12
C07D 401/14
C07D 405/14
C07D 231/16
C07D 401/12
C07D 403/14
C07D 405/12
C07D 409/12
C07D 409/14
C07D 413/12
C07D 417/12
C07D 417/14

Abstract:

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I):including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.